1. Shaw-Stiffel TA. Chronic hepatitis. In: Mandell GL, Bennett JE, Dolin R, et al (eds.) Principles and Practice of infectious diseases. 5th ed. New York: Churchill Livingstone; 2000, pp. 1297-1321.
2. Shimotohno K. Hepatitis C virus and its pathogenesis. Cancer Biol 2000;10:233-40.
3. Malik IA, Luqman M, Ahmed A, et al. A clinico pathological study of viral hepatitis. Pak J Med Res 1987;26: 4-11.
4. Rafiq M, Isomura S, Yamamoto N, et al. Prevalence of hepatitis G RNA and associated HbsAg HCV-Ab viral markers among professional blood donors/drug addicts in Pakistan. J Coll Physicians Surg Pak 1999;9:450-2.
5. Rodriguez-Rosado R. Impact of antiretroviral treatment on Hepatitis B virus infection in human immunodeficiency virus-infected patients. Abstract and poster presentation 59 at the 3rd international conference on Therapies for Viral Hepatitis. 1999, Dec 12-16; Maui, USA and Antiviral Therapy 1999; 4 (Supplement 4), 20.
6. Anne ML. Role of hepatitis B,C and D viruses in dual and triple infection:influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interferencre. Hepatology 2001;34:404-10.
7. Fingerhood MI, Jasinki DR, Sullivan JT. Prevalence of hepatitis C in a chemically dependent population. Arch Inter Med 1993,153:2025-30.
8. Bac CD, Stroffolini T, Gaeta GB, et al. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma. A multicenter Italian study. Hepatology 1994,20:1225-30.
9. Suga M, Senota A, Arima K, et al. Prevalence of HBV and HCV infection in Japanese patients with hepatocellular carcinoma. Hepatogastroenterology 1994; 41:438-41.
10. Alter MJ, Kruszon-Moron D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341: 556-62.
11. Farooqi JI, Farooqi RJ. Relative frequency of hepatitis B and C virus infections in cases of hepatocellular carcinoma in North West Frontier Province, Pakistan. J Coll Physicians Surg Pak 2000;10:128-30.
12. Malik IA. Spectrum and pattern of viralhepatitis in Pakistan. Eastern Mediterranean Advisory Committee on health research, 18th session (WHO), 1995.
13. Umar M, Bushra H, Shuaib A, et al. Spectrum of chronic liver disease due to Hepatitis C virus infection. J Coll Pjysicians Surg Pak 2000;10:380-3.
14. Esumi M and Shikata T. Hepatitis C virus and liver diseases. Pathol Int 1994;44:85-95.
15. Jonas MM. Hepatitis C infection in children. N Eng J Med 1999;341:912-13.
16. Malik IA, Ahmed N, Luqman M, et al. Hepatitis C as a cause of chronic liver disease in Northern Pakistan. J Pak Med Assoc 1992;42:67-8.
17. Malik I, Ahmed, N, Butt SA, et al. The role of hepatitis B and C viruses in the aetiology of hepatocellular carcinoma in northern Pakistan - a preliminary report. J Coll Physicians Surg Pak 1995;5:26- 8.
18. Malik IA, Tariq WUZ, Samma MA. The prognostic significance of hepatitis B and C viruses in the evolution of chronic liver disease. Pak J Pathol 1995;6:53-54.
19. Wejstal, WA, Norkrans G. Hepatitis C Virus infection with progression to hepatocellular carcinoma: a report of five prospectively followed patients in Sweden. Scand J infect Dis 1993;25: 417-20.
20. Alter MJ. Review of serologic testing for hepatitis C virus infection and risk of postrransfusion hepatitis C. Arch Pathol Lab Med 1994;118:342-45.
21. Alter MJ, Sampliner RE. Hepatitis C and miles to go before we sleep. N. Eng J Med 1989; 321:1538-40.
22. Kew MC. Hepatitis C virus and hepatocellular carcinoma. FEMS Microbiol Rev 1994;14: 211-19.
23. Bruix J, Calvet X, Costa J, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; 2:1004-6.
24. Durrani AB, Rana AB, Siddiqi HS, et al. The spectrum of chronic liver disease in Balochistan. J Coll Physicians Surg Pak 2001;11:95-7.
25. Chiaramonte M, Stroffolini T, Vian A, et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85:2132-7.
26. Uchida T, Kaneita Y, Gotoh K, et al. Hepatitis C virus is frequently coinfected with serum marker-negative hepatitis B virus: Probable replication promotion of the former by the latter as demonstrated by in vitro cotransfection. J Med Virol 1997;52:399-405.
27. Villa E, Grottola A, Buttafoco P, et al. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological marker of hepatitis B. Dig Dis Sci 1995;40:8-13.
28. Colombo M, Choo QL, Ninno ED, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2: 1006-8.
29. Mimms LT, Mosley JW, Hollinger BF, et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. Br Med J 1993;307:1095-7.
30. Sagnelli E, Coppola N, Scolastico C, et al. Virologic and Clinical expressions of reciprocal inhibitory effect of hepatitis B,C and delta viruses in patients with chronic hepatitis. Hepatology 2000;32:1106-1110.
31. Yano Y, Yamashita F, Sumie S, et al. Clinical Features of hepatocellular carcinoma seronegative for both HbcAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. Am J Gasteroenterol 2002;97:156-61.
32. Shaikh S. Portal systemic encephalopathy in chronic liver disease: Experience at Peoples Medical College, Nawabshah. J Coll Physicians Surg Pak 1997; 8: 53-55.